Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 Mar 26;27(16):4468–4477. doi: 10.1158/1078-0432.CCR-20-3600

Figure 4.

Figure 4.

Schematic of T-cell engagers and chimeric antigen receptors.

Bispecific T-cell engagers (BiTEs) have a CD3 binding moiety that can interact with the native T-cell receptor (TCR) fused to an antigen binding moiety that can target tumor antigens such as B-cell maturation antigen (BCMA) bringing T-cells into proximity of the tumor and inducing immune synapse and cytotoxicity. Chimeric antigen receptor (CAR) T-cells contain are genetically engineered to express a chimeric protein that includes an extracellular scFv domain capable of binding tumor antigens such as BCMA fused to a transmembrane (TM) domain, the CD3ζ stimulatory domain and a costimulatory (costim) domain, typically 4-1BB or CD28. Binding of the CAR to antigen leads to immune synapse formation and cytotoxicity. Created with BioRender.com.